MMP2 and prostate carcinoma: In summary, our findings suggest that the MMP-2-1306 C/T polymorphism is associated with elevated risk of prostate cancer, but MMP-1-1607 1G/2G polymorphism may have an inhibitory effect on the risk of prostate cancer in Caucasians.